Skip to main content
AUTL logo

AUTL · Autolus Therapeutics plc · Webcasts, Transcripts & Audio

Track AUTL — free
$1.14 -0.03 (-2.56%) At close · Nov 16 Play latest call Q1 2026 earnings call transcript
Market Cap
$303.43M
Shares
266.16M
Volume · Nov 16 2.35M Avg daily vol (3M) 2.13M

Autolus Therapeutics plc Webcasts

Earnings calls, investor updates, investor days and conferences for Autolus Therapeutics plc (AUTL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-17
Autolus Therapeutics plc (AUTL) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-10
Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call
Revenue
$41.24M
▲ 94.6% YoY
Diluted EPS
$-0.21
Gross margin
56.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-11
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call
Revenue
$45.69M
▲ 118.4% YoY
Diluted EPS
$-0.15
Gross margin
55.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-30
Autolus Therapeutics plc (AUTL) June 30, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-30
Autolus Therapeutics plc (AUTL) June 30, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Autolus Therapeutics plc (AUTL) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Autolus Therapeutics plc (AUTL) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-02
Autolus Therapeutics plc (AUTL) June 2, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-02
Autolus Therapeutics plc (AUTL) June 2, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-14
Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript
Confident tone Commercial launch of Ocastle Gross margin improvement Revenue and full-year guidance
Revenue
$26.22M
▲ 191.9% YoY
Diluted EPS
$-0.27
Gross margin
6.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Investor Update
Investor event
2026-04-08
Autolus Therapeutics plc (AUTL) April 8, 2026 Investor Update Transcript
No reported result — non-financial event
Audio Transcript Slides
Investor Update
Investor event
2026-04-08
Autolus Therapeutics plc (AUTL) April 8, 2026 Investor Update Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-27
Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript
Confident tone Pipeline expansion (OB-Cell, Catalyst, Carlyle, Lumina) Safety/efficacy in real-world setting ROCCA real-world data consortium
Revenue
$24.29M*
▲ 83655.2% YoY
Gross margin
-4.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript
Confident tone Obe-cel U.S. Commercial Launch Market Share Growth in ALL Pipeline Expansion
Revenue
$21.19M
Diluted EPS
$-0.30
Gross margin
-35.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript
Positive tone Obe-cel US commercial launch Obe-cel regulatory and EU/UK market access Pipeline expansion (pediatric ALL, autoimmune)
Revenue
$20.92M
Diluted EPS
$-0.18
Gross margin
-16.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript
Confident tone Commercial launch of AUCATZYL Pipeline expansion into lupus and other indications Manufacturing and dosing variability risk
Revenue
$8.98M
▼ 11% YoY
Diluted EPS
$-0.26
Gross margin
-99.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Call Transcript
Confident tone AUCATZYL U.S. commercial launch CARLYSLE autoimmune study Center onboarding and patient access expansion
Revenue
$29,000*
Gross margin
-39165.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript
Confident tone AUCATZYL FDA approval and launch readiness Pipeline data presentations at ASH SLE and pediatric pipeline expansion
Revenue
$0
Diluted EPS
$-0.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call
Revenue
$0
Diluted EPS
$-0.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-17
Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript
Confident tone Obe-cel regulatory progress and PDUFA Pipeline expansion into autoimmune (SLE) FELIX study results and persistence/disease burden
Revenue
$10.09M
Diluted EPS
$-0.24
Gross margin
100.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript
Confident tone FELIX study clinical data Pipeline expansion into autoimmune obe-cel BLA review and regulatory progress
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–21 of 21 webcasts
Key facts CIK 1730463 CUSIP 05280R100 13F (30d) 86 filings 71 filers Visit website Investor relations